1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: During the three months ended September 30, 2024, none of our directors or executive officers adopted or terminated any contract , instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.
+Added: During the three months ended March 31, 2025, none of our directors or executive officers adopted or terminated any contract , instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.
The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.
Description of Document
−Removed: Amended and Restated Open Market Sale Agreement SM , dated August 2, 2024, by and between Rigel Pharmaceuticals, Inc.
−Removed: and Jefferies LLC (filed as an exhibit to Rigel’s Registration Statement on Form S-3, dated August 2, 2024 and incorporated herein by reference).
Amended and Restated Certificate of Incorporation (filed as an exhibit to Rigel’s Current Report on Form 8-K, dated June 24, 2003 and incorporated herein by reference).
5 unchanged sentences
Specimen Common Stock Certificate (filed as an exhibit to Rigel’s Current Report on Form 8-K dated June 24, 2003 and incorporated herein by reference).
−Removed: Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd., dated September 3, 2024 .
−Removed: Supply Agreement with Kissei Pharmaceutical Co., Ltd., dated September 3, 2024 .
−Removed: Amendments to Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd., dated October 29, 2018 .
Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.
9 unchanged sentences
Filed herewith.
−Removed: Indicates a management contract or compensatory plan or arrangement.
−Removed: Certain marked information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private and confidential.
* The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
4 unchanged sentences
(Principal Executive Officer)
−Removed: November 7, 2024
Chief Financial Officer
(Principal Financial Officer)
−Removed: November 7, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.